Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study

CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591

Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research